Clinical trials
Observational Coronary Artery Disease trials in Brazil
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Unknown status | 6 |
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Sao Paulo General Hospital | 5 |
| Scitech Produtos Medicos SA | 4 |
| University of Sao Paulo | 4 |
| Hospital Israelita Albert Einstein | 2 |
| Instituto Dante Pazzanese de Cardiologia | 2 |
| Terumo Europe N.V. | 2 |
| AstraZeneca | 1 |
| Bayer | 1 |
| Cordis US Corp. | 1 |
| Federal University of São Paulo | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Coronary Artery Disease | 29 |
| Atherosclerosis | 4 |
| Cardiovascular Diseases | 3 |
| Coronary Disease | 3 |
| Peripheral Arterial Disease | 3 |
| Acute Coronary Syndrome | 2 |
| Thrombosis | 2 |
| Angina Pectoris | 1 |
| Angina, Unstable | 1 |
| Coronary Occlusion | 1 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.